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S10 3. New therapies
40* Aztreonam lysine for inhalation (AZLI) for CF patients with
P. aeruginosa (PA) infection
K. McCoy1, G. Retsch-Bogart2, C. Oermann3, R. Gibson4, A.B. Montgomery5.
1Ohio State Univ., Columbus, OH, USA; 2Univ. North Carolina, Chapel Hill, NC,
USA; 3Baylor Coll. Med., Houston, TX, USA; 4Univ. Washington, Seattle, WA,
USA; 5Gilead Sciences, Seattle, WA, USA
Background/Methods: This was a Phase 3, double-blind, randomized, placebo
(PL) controlled study of AZLI, a novel, inhaled formulation of aztreonam. Patients
received 28 days of tobramycin solution for inhalation (TSI) followed by 28 days
of 75mg AZLI or PL (1mL) administered BID or TID by the PARI eFlow®
electronic nebulizer over ~2 minutes. Inclusion criteria included age 6 years, PA
in sputum or throat swab, FEV1 25% to 75% predicted, and use of 3 courses
of TSI in the prior year. Concomitant standard CF therapies were allowed. The
primary endpoint was time to need for IV or inhaled antipseudomonal antibiotics
for predeﬁned symptoms of pulmonary exacerbation (increased cough, decreased
exercise tolerance, increased sputum/chest congestion, and/or decreased appetite).
Results: 246 patients enrolled and received TSI; 211 subsequently received either
AZLI (n = 135) or PL (n = 76) (mean age 26 years, mean FEV1 55% predicted).
The median time to antibiotic need was at least 21 days longer for AZLI-treated
patients compared to PL-treated patients (p< 0.05). After 28 days of treatment,
FEV1 improved by 6.3% and PA CFU density decreased by 0.7 log10 for AZLI-
treated patients compared to PL-treated patients (p< 0.05). AZLI-treated patients
had signiﬁcant improvement in respiratory symptoms, with mean improvement of
>5 compared to PL in CFQ-R respiratory domain score (p< 0.05). AZLI was safe
and well tolerated. The adverse event proﬁle was consistent with CF lung disease;
the most common AE was cough.
Conclusion: AZLI is a promising new therapy to improve respiratory symptoms
and FEV1 in CF patients with PA.
Funded by Gilead Sciences, US FDA, and the CFF.
41* PTC124 activity in CF patients carrying stop mutations: results of
a phase 2 study
E. Kerem1, S. Hirawat2, S. Armoni1, Y. Yaakov1, H. Blau3, J. Rivlin4,
M. Aviram5, D. Shoseyov1, M. Cohen1, V. Northcutt2, G. Elfring2, L. Miller2,
M. Wilschanski1. 1Hadassah University Hospital, Jerusalem, Israel; 2PTC
Therapeutics, South Plainﬁeld, NJ, USA; 3Schneider Children’s Hospital, Petach
Tikvah, Israel; 4Carmel Hospital, Haifa, Israel; 5Soroka Medical Center, Beer
Sheva, Israel
Aim: PTC124 is a molecule that promotes ribosomal read-through of nonsense
mutations in mRNA. The pharmacological activity of PTC124 was determined in
CF patients carrying stop mutations.
Methods: Patients received 2 cycles of oral PTC124 comprising 3 times per day
(TID) dosing at 4, 4, and 8mg/kg for 14 days and no treatment for 14 days, and
then TID dosing at 10, 10, and 20mg/kg for 14 days and no treatment for 14 days.
Nasal potential difference (NPD), pulmonary function, weight and CF symptoms
were assessed before and at the end of treatment in each cycle.
Results: 23 patients (median age: 25, range: 18−57 yrs; genotypes in-
cluded G542X/W1282X [1], G542X/delta F508 [3], G542X/N1303K [1],
W1282X/W1282X [3], W1282X/3849+10C to T [1], 3849+10C to T/delta F508
[1], and W1282X/delta F508 [13]) received both dose levels. At both doses, mean
chloride conductance (average of the 2 nostrils) improved from +1.1 to −5.8mV
(p 0.0001) and from −0.3 to −3.9mV (p = 0.032), and normalized to >−5mV
in 56% (13/23) and 35% (8/23) of patients, respectively. At the end of low-dose
treatment, mean FEV1 increased from 63.6.6 to 66.7% of normal (p = 0.02), FVC
increased from 77.0 to 80.1% of normal (p = 0.01), and mean body weight increased
from 57.0 to 57.7 kg (p 0.001). Side effects were minimal.
Conclusions: Treatment with PTC124 in CF patients carrying stop mutations is
associated with improvements in NPD, pulmonary functions, and weight. Longer
term studies are in progress.
42* Validating assays on invasive airway samples as end-points for
gene therapy trials.
J. Davies1,4, U. Griesenbach1,4, C. Boyd3,4, S. Hyde2,4, D. Gill2,4, D. Porteous3,4,
E. Alton1,4, on behalf of the UK CF Gene Therapy Consortium. 1Imperial College,
London, United Kingdom; 2University of Oxford, Oxford, United Kingdom;
3Edinburgh University, Edinburgh, United Kingdom; 4UKCFGT Consortium,
United Kingdom
We are working towards a trial of CFTR gene therapy, designed to look for clinical
beneﬁt. A strong focus has been on the development of molecular, functional and
clinical end-points, which we are validating in a series of observational studies.
Several assays are designed for samples obtained by invasive procedures. This
study was performed to assess the feasibility of obtaining and processing samples
for such assays and to allow CF/non-CF comparisons.
Healthy volunteers (HV) underwent a bronchoscopy, nasal biopsy and brushing.
16/20 HV screened were included (2 CF heterozygotes, 1 pregnant, 1 withdrew).
We did not consider it ethically justiﬁable to ask a CF subject to undergo a
research bronchoscopy and therefore obtained samples (5 endobronchial biopsies
& 5 bronchial brushings) from those undergoing a clinical bronchoscopy or a
general anaesthetic. Bronchial samples were obtained from 15 (14 children), nasal
biopsies from 6 (adults) and nasal brushings from 21 (11 adults). There were no
complications of any procedure.
Of the assays attempted, some could not be performed (short circuit current
measurements on biopsy samples), others were shown to need further reﬁnement
(immunohistochemical staining for CFTR protein) and others were successful
(airway surface liquid height measurements, microarray & TaqMan analysis of gene
expression, bacterial adherence).
The study achieved its aims of allowing us to exclude some assays from the clinical
trial protocol, focus on reﬁning others and use those successful assays to perform
power calculations for detecting change after a therapeutic intervention.
Supported by: UK Cystic Fibrosis Trust.
43 Lentiviral vector-mediated expression of RNA interference
sequences for ENaC in cell models of human airway epithelium
E. Copreni1, L. Palmieri1, S. Castellani1, F. Tilesi2, F. Ascenzioni2, M. Conese1.
1Institute for Experimental Treatment of Cystic Fibrosis, H. S. Raffaele, Milan,
Italy; 2Department of Development and Cellular Biology, University of Rome “La
Sapienza", Rome, Italy
In cystic ﬁbrosis (CF) the hyperactivity of the epithelial sodium channel (ENaC)
leads to the depletion of the perciliary liquid layer and the inhibition of mucus clear-
ance, which results in chronic infection of the airways by opportunistic pathogens.
We developed a HIV-based lentiviral (LV) vector containing a siRNA cassette to
efﬁciently knockdown the expression and activity of ENaC in human respiratory
cells. A siRNA cassette (alphaA2) for the alpha subunit of human ENaC was cloned
in a LV vector carrying the NGF-R (Nerve Growth Factor Receptor) marker gene.
H441 cells, derived from lung adenocarcinoma, were incubated with various doses
of the LV vector and the conditions that gave rise to high efﬁciency transduction
(64−91%) were determined. Accordingly, H441 cells were transduced with the
alphaA2 siRNA-LV (2000 M.O.I.); 96 hours later ENaC genes were induced with
dexamethasone (DEX, 50 nM, 6 hours) and alpha, beta and gamma subunit mRNA
content was determined by quantitative real time PCR. We demonstrated that
alphaA2shRNA-LV transduction induced inhibition of alphaENaC mRNA down
to 40−50% both in un-induced and induced conditions. Reduction in the amount
of beta and gamma mRNA was also observed. Our study shows that a LV vector
can down-regulate the expression of alpha, beta and gamma ENaC subunit mRNA
in H441 cells. To further characterize the potential of LV-mediated down-regulation
of ENaC, functional studies are under way.
Supported by: The Italian Cystic Fibrosis Research Foundation, the Associazione
Lombarda Fibrosi Cistica and EU grant n. 005213.
